0001437749-13-002694.txt : 20130312 0001437749-13-002694.hdr.sgml : 20130312 20130312160248 ACCESSION NUMBER: 0001437749-13-002694 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130312 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130312 DATE AS OF CHANGE: 20130312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 13684172 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdli20130312_8k.htm FORM 8-K pdli20130312_8k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


 

FORM 8-K


 

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): March 12, 2013

 

PDL BioPharma, Inc.


(Exact name of Company as specified in its charter)


000-19756
(Commission File Number)


Delaware

 

94-3023969

(State or Other Jurisdiction of

 

(I.R.S. Employer Identification No.)

Incorporation)

 

 


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)


(775) 832-8500
(Company’s telephone number, including area code)


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 
 

 

Item 8.01 Other Events.


On March 12, 2013, PDL BioPharma, Inc. issued a press release announcing that it has paid the March 12, 2013, regular quarterly dividend payment. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.

  

Description

99.1

  

Press Release

 


 

 
 
 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 



PDL BIOPHARMA, INC.

(Company)

By:

/s/ John P. McLaughlin

John P. McLaughlin
President, Chief Executive Officer and Acting Chief Financial Officer

 


Dated: March 12, 2013

 

 
 
 


 

EXHIBIT INDEX


Exhibit No.

  

Description

99.1

  

Press Release

 

 EX-99 2 pdli20130312_8kex99-1.htm EXHIBIT 99.1 pdli20130312_8kex99-1.htm

Exhibit 99.1

 

 

 

 

Contacts:

John P. McLaughlin

Jennifer Williams

PDL BioPharma, Inc.

Cook Williams Communications, Inc.

775-832-8500

360-668-3701

John.McLaughlin@pdl.com

jennifer@cwcomm.org

 


 

PDL BioPharma Completes Regular Quarterly Dividend Payment

 

INCLINE VILLAGE, NV, March 12, 2013 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2013, the record date.

 

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.  

 

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

 

# # #

 

 

 GRAPHIC 3 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_[0ID4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``2`````$``0!(`````0`!.$))300-```````$````>#A"24T#\P`` M````"```````````.$))300*```````!```X0DE-)Q````````H``0`````` M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`& M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$)) M30/X``````!P``#_____________________________`^@`````________ M_____________________P/H`````/____________________________\# MZ`````#_____________________________`^@``#A"24T$`````````@`! M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X M0DE-!!0```````0````".$))300,``````BU`````0```'`````I```!4``` M-=````B9`!@``?_8_^``$$I&248``0(!`$@`2```_^X`#D%D;V)E`&2````` M`?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X. M#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M_\``$0@`*0!P`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!```````` M``,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``! M!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($ M!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\` M]*ZGU/#Z5AOS,Q^RIF@`UVO3>YK?S%:QX@!9UM%OI74^J8?5>AU9F$_? M4ZUH<.',=#MU=S?\&]JR,?'R,JSTL=ILL@NVR!H(GZ9;^\NEZ+@='IZ173TT M,MP;F[C9HXV[OIVW._/L=^?^Y_-^Q8^'DX'3NJV65O=;BAKF,T.;`G^4Z5SU%%E]U=%8E]C@T1][G?U6-]R M"G3^LW_*%?\`Q(_ZIZH8^%FY+"_'J=8UIVD@CGF/<0K_`-9O^4*_^)'_`%3U M>^J_]#N_XT_]2Q)3AV5]1P7`O%N.3]%P)`)\-S#L6UT3K5N18,3+(=8035;$ M;HU^L9/[ M3_ZTS\MBTOJS_P`GO_XUWY&K-^LG_*?_`%IGY;%I?5G_`)/?_P`:[\C4E.ND MDD@I_]#T'K_0,3K>)Z-WZ.^N3CY`$N8X_P#5U/\`\+5^>O-_V!U?]K?L;T/U MWGOZ?IS'VOU8_HW_`$]_Z#^?]B]<30)W1KQ/>%)#*8BM^RJ>:MZ17T'ZO-PL M:U[C;:#DV$D;W/'Z2&3MJK=L_FV?]/WJGTO"9G9?V=[S6W8Y\MB9!:(]W]9= M#US/Z9@8;;NIL-E#K&L:T,-AWNW;/8)\%6Z3U3H.5DVUX5)HS:&%SZ+*'47; M#&K66LK9='[ MH_=;_54^G9ASL.O*./=B&R?T&0W9:V"6_I*Y?MW;=R+?<^LW_*%?_$C_JGJM@]7R<"MU5+:W->[>2\$F8#?S7-_=5^CZQ_5 MCJN1CML8X690#<6S)H>QMFOT*;[6>D_W?RT?I;NC]2MS:Z\%M9P,AV*\O8R' M.8`=[-L^SW?G(F,AN"*4Y&=UC,S&>G<]K*M"6,$`Q^\7%SG*WT#IEMN0S,M: M6T5:USH7N[.;_(9^\MUG3L"L[F8U33XA@G\BLH*>5^LG_*?_`%IGY;$##ZOF M851IHV;"XN.YI)D_VF^"ZJ[!P[W^I=178^(W.:"8';5#_973?^XM7^8$E.!_ MSCZG_P`%_F'_`,FMGHF=D9V*^V_;N;86C:($`-/B[]Y&_973?^XM7^8$>C'H MQVEE%;:FDR0P`"?'1!3_`/_1]522224\S]?S'2,4[O3_`%VB'G\TR[])K_H_ MIJETO(;_`,Z;ZWY;.LY#\)W^4*H:,=C73]E=5078_P"E=^D]7^=6I]=/^26? M\>S\CU7^I?\`R;D_'^#E-'^;^U#B8^7>[ZL_5RG)R;:NG9E]E?4,D6.:X@/L M]"FS)W;ZZ[G>U_O5ZAU.-U;JO3NDW.NZ4WISK;Z_4=;73D'A?4G_P`1^1_U[_J$X]?.7]WYO^FI!]6^B9W5 M>B]&?E95;>F8A9D48]59]5SF%VP7Y#WN_P#`J_\`R:KMZ=1EXOUIRK;+0_$R M\E^.VNU];66,;ZGK[*G-:ZW\S])_@UU7U5_\3V#_`,7_`!,7I319A4B^S;78ZEUWJ_3W/= MN;[/471=>_Y4Z+_X9=_U"K-_G_K/_4;_`.>'I1XJ'E^/&ISK\^K.P^AX.77] MJR;\/[2ZS)RK,6B`UC7ON?2'NRLC]QFS_A5<^I];,_IN37;:ZUF+EW58SV6N M?MJ(8[TZLBR+;:=?T;[/\&LKZU_^)7HGQJ_ZEBZGH7\_U7_PZ_\`ZBM-E7`: M[_MZ)?_9`#A"24T$!@``````!P`(`````0$`_^(,6$E#0U]04D]&24Q%``$! M```,2$QI;F\"$```;6YT`",`*``M`#(`-P`[`$`` M10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R M`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0&!YD' MK`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED M"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+ M:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V. M#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0 M"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C M$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5 MFQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO M&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(< M*AQ2''LP>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_ M'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0C MPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=! M*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P M1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B M8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI M0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@ M<3IQE7'P,QY M*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K M@%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z* M9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY-- MD[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+ MIOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6P MZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LN MNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+QHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U M4/7>]FWV^_>*^!GXJ/DX^H6&AXB) MBI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN_*3`_&[Y'9R"C[PH::+ M';#W[DIHX*7MVDI8M,6*RT\A2.#LBG@C^I(7,JI9;5099J\[\D-MC2[MM,9. MW$U=!QB)\Q_PO_CG^EX;AFU=K?%_AZ-+_-#=TPW3FAW2^3WK?2S+>U+MJUP" M`;>XW@XMTI'507GG_P".TO\`U,?_`(K[4=>Z[\U1_P`=9O\`DM_^*^_=>Z?, M#N[=>U:Z+);:W)GMOY""19(JO#Y:NQU0CH0P/DI)XF(N.0;@_0^]$`\1U[JX M3X9?,S+=CY:FZI[5J8)]V3T\C;5W4(X:4[A-'`TT^(R\,2QTZYA::)I(9HU1 M:E49642A3*GDCT]R\.O=(/\`FBR2)/TMH=TO#OVX5V4'U[0^H!`)'NT'XNO# MJIKSS_\`':7_`*F/_P`5]O\`7NNUJ:A2&6HF5AR&65P1_K$-<>_=>Z$;:'=?>';VY*&-:+%[EJ5!88VNH@3#C?_CM+_P!3'_XK[5];ZVC.FB3U#U6222>N-D$DDDDG;6,)))Y))]H6^)OM MZUT)/O77NO>_=>Z][]U[K__0OJ_FS_S9J?I*FSWQJ^-6?@J^XZN";&=B=B8J M>.HI^JJ:=#'4X'`U,1>.7L2:)B)902N&4_\`*X0*:4N1^2#N)BW?=XB+`&L< M9_T3^DW_``OT'X_]+Q333:>U3W=:A-34U%943UE9/-55=5-+4U554RO/45-1 M.[2SSSSRLTDTTTC%F9B69B23?W.H`4!5%%'`=(^AL^./1';OR-[=VGUATGAZ M_);YR=?!64V0I9JBAH]J4=#40RU.[LUFJ=2V"Q&!)65ZK_.!]"1!YWBC8NW; M\W&0"V`I0Y+$_A`_$6X4_;BIZLJLQ`7CUO:[[^)&X.R_CGUUUQV-V M96[\[DZXVW!!3]KY.BCQR[FW)]G!#DY>^NKBTM1#:NY*Q@U"@\!7_`%#R&*=&2U``)J>JB^L]E;BV)\E^L]F[ MSPTV*S>)[6V51Y'&UT2NC`[DQVF1"0\%90U<)#Q2*6BFB8,I*GW0D,A(X4ZM MULA?P+"?\Z;%?^>^D_Z\^TE3Z]:ZK-_F2=?=?46PMJ[YIL=B\/O@[II\#!-0 M4]/25.=PT^.R-56PUL4"1FK7&34T+QS."8?(4O:0#V]"34CRZV.JE]B9C(;> MWOM#.XEY8\GA]S8+)4+0EA)]U1Y.FGA5=/)UN@4C\@V/!]OD5!'7NK//YHW, M_2OX_9W[Q_3U[0]LP<&Z\.B"_&VEI:[OSJ&CK::GK*2IW]MR&HI:J&.HIJB& M3(1*\4T$RO%+&X-B&!!]N/\`"WV=>ZV/6Z\V`ZE'V-L]U8$,K;9PK*P/U!4T M1!!]I*GU/6NJZ?G%\5-@4G7F6[;Z]V_C]J9S:\M)4[AQF$IXZ'#YK#5E9#15 M%0,7`$HZ/)8^>J2;R0K&)(1('#-H*O1.:Z2<=;ZIVH*^LQ==19/'U$M'D,=5 MTU?0U<#%)J6LI)DJ*:HA<TZJJB4#@"*ID=?]A[3(*2@?;UKJA'VJZWUM(],_\R@ZJ_\` M$<;(_P#>9QGM"WQ-]O6NA)]ZZ]U[W[KW7O?NO=?_T3K_`,V?^51E_CUE\_\` M(_H7&Y+.]%YS(SY/>^VT>JRF8ZDR^3J3)/6/-,T];D=@9&LG_:JI&>7'2N(: MABABE:?.1^=8]UCBVG6DR&W\I,@EQNX ML"]9-+3`N*6IUM%.+,LD09YIY:M^9;`0.^BZCJ8WS0,>(8>:M0`^8XCT+D)3Y3]-U/0NW/D;0[AEJ>NMY8"DSNTGEHJB@S>?:OBD:EP]'AZ]:>J& M6::)XY$8!(O&[LXB4R>\:;RQN;"\N+"Y2ES$Q5A4$`CYC%.C!2&`(X=47=M_ M(G?/:G:]'VM)-%@,IMVKH9-E4M!%3RC;5)B*]LCB8Q--`?XC5PUC&:2696$D MK&RK'IC7RH%73U;I2?[.C\G/^?KY7_SS;7_^L?O7AI_#U[H'>PNU>P^ULC2Y M7L+=>4W16T,#4U":YX8Z:A@=@\J4=#214U#2F9E!D:.-6D*C4386L%"\!U[H MT7PG^.6;[5["PV^LSCIJ?KC9.5I\M55]3$Z4^XV5T/NC;=;6T[;CW]3 M0X#`XCRH:N>&2MII4C3YFC2]V]N1*2P/D.O#K7T]J^M]7 MD=T8*LVS_+OI<'D$:.NQ_7_5D=9$P(:"JDW!M.>>!@>0T$DI0_XK[3+F;\SU M[SZHW]J>O=;2/37_`#*#JK_Q'&Q__>9QGM"WQ-]O6NA)]ZZ]U[W[KW7O?NO= M?__2W[,ACZ#+4%=BLK0T>3Q>3HZG'Y+&Y"FAK:#(4%;"]-64-=1U*24]71U= M/(T M\+69/H#)U;5F[=IT:S5M?TW7UDPNZ#]RHJNNJNHE"T]0Q9\8[""U[I(!N@%%8X$H'^"0>8_%Q&:CI%-#I[E^'_!U._E._P`IVM^0U;A/ MD5\BL)58_HC'U4=?LK95?'+25O<-;22WCK:V,^.>FZXIIX[.XTOEG4QQD0"2 M1J\[\[KM2R;5M4@.YD4=QD1`^0_X9_QWB,VS MTAC<;24V/QV/J=VT5!CZ&"*DHJ*CI,?MBGI:2DI(%C@IJ:E@0)'&BA40`*`. M/<&1LSO([L2Y-23DDGB2?7I<.JSNH<#BMT]K=:[:SE,:S"[@WYM/"Y:D$T]. M:K&Y/.T-'6TXJ*:2*H@,U-,RZXW5UO<$'GVZQHK'Y=>ZO;_V17XN_P#/MW_] M"[>O_P!D/M+XC_Q=:KTXXSX3_&/$U<5;!U?15,L+!DCR>Z,YCL;CL/0TN,Q-!1XS&T,*T]%C\?30T=%20) M^B&FI:=(X((E_"JH`]TZ]U4S_-'_`.!'2W_+'?O_`$/M#VH@X-UL=56X/-Y; M;67QN?P.0J<5F<160U^,R5&_CJJ*MIG$D%3!)8Z)8G%P?Z^WB*BAX=>Z&IOE M3\BW4J>X=\`,+$KEG1O]@Z(KJ?\`$$'W70G\(Z]3H&<_N/<&ZLE-F=S9S+;A MR]183Y/-Y&KRE=*H)*H]56RS3%$+'2M[+?@>[``8`Z]T=#X@?$[<7;.Z&(J<9U;A*R#)2S9"!X#O.HI9!-3X?%0RA7J,7+,@^[J0/%X@T:,9&]#?.4`?%SLP```)M,`#@`#>VW+`#\`>V8OC7K76NU[5];Z%:B[U[JQ MM%28[']L]C4-!04L%%0T5)O+<$%+1T=+$L%-2TT$5>L<-/!"@5$4!54``6]U MTK_".O=2?]F"[V_Y_'V;_P"AON/_`.N/OVE?X1U[H?/B[W5V_N'O_J["YWM# M?^9Q&1W&*>OQ>3W9G*['UL!H:US#54E36RP3Q%D!LRD7`/U]U=5T-@=>ZO\` M_:3K77__T]_CW[KW4/(8^@RU!78K*T-'D\7DZ.IQ^2QN0IH:V@R%!6PO35E# M74=2DE/5T=73R-'+%(K)(C%6!!(]V5F1E=&(<&H(P01P(/D1U[KE0T-%C**C MQN-HZ7'X['TM/0T%!0T\5)14-%21)!2T='2P)'!34M-!&J1QHJHB*```/?F9 MG9G=B7)J2Z!?NO8G1.^*?;T?=XVR:?'39)]N_WCW5+MA?-4I1KD MOM'BS&(-8Q2&'6"7T>GZ7Y1Z0I.Q-IU/;V(PZ;@RG7,.8I' MW=0822GH:I,I588/]W%1/39.G<2%=.F9#^1[<;;KY;)-Q:T<6#-I$E#I)SBO M"N#^SK6I:Z:]W0H>T?6^HU;6T>.I*G(9"KIJ"@HH):JLK:V>*EI*2F@0R35% M34SND,$$,:EF=V"JHN3;WM59V"HI+$T`&2>O=`%O7:/QP^0E;A*+=%;LKL'( M8%[@4L]O(B^I4@ M?S'6@1Y'HO'8G4G\OGJ7=W76P^Q\?M;:.[^V\O\`P'K?`Y7H47YX4VFW[G?07=S:6[R00+JD84HHH34_D"?RZ M\7`(!.3T,/\`LD?Q@_Y];2?^A'O#_P"R#V@\1_XNMUZ5.VOBI\>-IU<-?ANJ M-K_>4[B2"?*PU>X&BD4W62-<_5Y...13]&`!!^GO1=SQ;KW1@(XTB1(HD2.. M-%CCCC4(D:(`J(B*`JHJBP`X`]UZ]TF-[;)VOV+MG);.WEBDS6V\N*49'&R5 M%72I4?95M/D*6\]#44M5&8:RDC<:'6Y6QN+CWL$@U''KW1??]DC^,'_/K:3_ M`-"/>'_V0>[>(_\`%UZO7O\`9(_C!_SZVD_]"/>'_P!D'OWB/_%UZO7O]DC^ M,'_/K:3_`-"/>'_V0>_>(_\`%UZO2BVG\3OC]L?<6)W9M?KVFQ>X,'5?>8O( M+G-S5+4E2(WB$JP5N:J*60A)&%G1AS]/>B[$4)QU[HQ7NO7NO__4W^/?NO=> M]^Z]U[W[KW6N1_/].TTROP7DWW#+4;)3L[?)WC#`M8U1-M,5/6+;CA@&/>/( M&67$+*%$#+,6MH(:Q]RQ[8>.4YD%L:7'@IHX?%^IIXXXTXXZ37%/TZ\*]%6Z M#P?QQWC_`#*/CC6_RODWAL#96UU&7[\;=>Y\WA,1FMKPULC9G$8+`]@;@J=Z M;C_BNW4FIIZ5(YH142P3+'&L4LZG6YR;M;\H[LO.1CEN'Q#I4$AJ8+,BZ%HU M"#@T!%34#JBZ3*OA8'GU;9L_MOK^K_G`=J=0T_0>Q,=V#C.DJ'/5_?\`3Y+, M-OS.8Q]L]=3+MVNQK_[AHZ&*#(0P!U_<\5'&;W)'L#SV-TO(=E?GD?%_,9^4/R)[)[6VY\"?C)M'M?KGI?,3;< MW)V=V7OI-JX_=NX*:2I63'[-H15XF,"K%*[TKR5%0STYCFG6F$L:,^>4]FVJ MSLIN9MXD@N[A=2QQIJ*J?-S0\*YP,U`K0]:\5V)$:5`ZR#YQX+YH?R_OG5%D M-DY'JWM[J+IKM[9W;O5^7JQD9MO9E]C[KIH:JAKFIJ*:JQ=;68BM@*3013T] M322Q.K`)++K^KDO+_-'+96X$UA/<1/%(!34-:\1FA`(."0001Y@;\37')BA` M->M?7&;:^`>,_ENX/L!-XRX#Y]T6;F=^;9;4V^KE@J-6I5TT\,5HU-1.O%#4 M<<4R$U(_"!K^IT>'Y@]A=L[WMV;R[:P7CW7N#;'C$&^MWY/&[N MZ@K\'B9TKE1H]W;DQ\-)',:A1)][.QE77J'L.[#:V,S>X=G82I'8MVJWX%!6 M4$X_"IK2GD,=..6'@%N/_%=6;[/_`)A_R9V/\N.I/C5\OOC5M#J:B^0%,[=: M9[8V_AO2?&9":6II\?C=Q54+SXW*RC)4ZT548%HG@DJ(IE22%O8.GY5V>YV* M^W?8MWDG:U/ZBNFBH\RHXC&16M:$5!Z<$CAU1U`KT9?Y&]P_.;;78=7MCXX_ M';JG<^Q,3M[#Y.K[2[>[1CVGBLOGLF]>:K;&"P-+-0Y$U&+@I8S)4R2-3LTX M%U*D$HVFPY;FM5FW;=9TN6<@1Q1ZB%%.XDU&:\...KLTE:*HI\^@O^.7\Q'. M]U_'/Y4]@;FZKHMB]U_$BF["H^P.O5W$?"K^8A\E?F9N?JS*[<^+-)@.AZ@[DPW=?<-1N-GH,#O&@PV? MRN+P^P\;756.R.9Q\$D>(IJVJ-/5`5-;*EHEB5W5\P\J[1R_#>I+O);Q:FFVY!M7#8IV%KN&_2*;H*(U$?=J)I5CD*M2H%WI.DM@1XW&]M;AWQV+&E=/ND5M!0;B@Z]P^+-)E*W:N&J< MK2)_$YX)9-<[JU,!32L:KR-LMONPV2_WY_WC+4Q*D>--"5UDU`8T/:".''(Z MWXSE=:IV^?5EV6^2W:N__BKU3WY\7.E(>TMX=O8_9>3Q6Q-T;OH-I8[:>-W+ MC:FMS>5W-N&>-*:>BVE4TIIY1$8FJ78&,BX4A!-HLK7>KW;-YW'P8("X+JI8 ML5-`%7U:M17AY].:B4#(M2>BJ=<_/[Y'[:^3_7OQ;^5_2G5^R,]W7A,[4]5[ M[ZFW[+O/;)SV(HLA41X?<>/GJ9ZV,35%#X'834TD\L;5-LM MYO.Q;C-(MN1XB2II:AID$4'G7SP#FHH:B1@X210*^G1R).R?E!]U1XV#J/;Y M(H\G6Y/<,HR"XT*=M8FMP=%08=I5(X!33([%Y$4"]/X]> MO__5W^/?NO=>]^Z]U[W[KW6O?_/1DR>/W?\``?<.+Q";AJML]P;GSL6W8\OA M\9DMPSXW)]75U/@\/%E:J%ZW)9:2F\$20QS-Y'4%3=0TI>VX1H.9HGDT*\"K MJH2%J)!4T&`.)K3I//QC/SZ+[W3OGM3YM?.7X:0Y/HW!_"/*]7[ZQVXVW'V[ MV+LS:G;F^J!MR[:R#X;;>W*Q]M;IW6R+@GI<90T-+D-=57RF1X8FD]FFWVUE MR[RYOY3!4^AO8@DDN7'^MGM MR`'5]6?(T^.3SI3^?5Q_N0WV=%I^"G:G9GP&J?D5U9UYT7N[YP=,YWM.LW)U MUVU\2WL1'E),32428'?55M"?/Q;6R4^"@QLE3!5M'544PD98:B&6*4F_ M,EE9\SKM5[=;E'MVX+"%DBN0T1I6NI`VG4*ZJ$8(ID$$=5C)C+`+J6OEUR^, M?6>>3XZ?S=^[.RMS=<8SO+O/8_<64W7T9MWL39^>W3U!3'']GY6:F[*QF-S, M\NRLI7;BSE3214N4^VJ*:/'/]P(Y&DCC]O%Y%^]N1=NM(93MMM)$%F:-@LN8 MQ^F2.\!0#5:@ZL5%"?(#IF8GN(..A[_E`X[X38_XP=.P[V?XGO\`)5,WO85! MR^5Z9RO<#2MO[/MML^3^I_Y M@7<>X_YA/4>\/D)U?O#'XQ?BQA*'LG#878.VL84AACCR>(RF\]J8W!H#&T%5 M/5NBQU2SU)AJ!*DR"#88Y[[E?;XN5KZ.UO(R?J28R78_(A&)]0!Y4%10CIMZ M"1O$%1Y=/?\`+GQ8I?CM_.$IL=B-AX'%93:6Y\A@\-UYOW;6^-B;>HK:5WQ\E0FY.U&JFQV1QN4@,S M]@;A9=59BJJLI'E^W,=QK+*+`@?3V$/<)M?-5XV::(^((_`OD0#T[!_9CHB7 M\J[$U5%_+]_F)4TKXQZBJW#WDT9H\W@Z^%?+TK!'&M56T&1J:.B97!N)I(]` M]1LO/L2W&13[H6+T;3V>35 M_LCY4K_+KP!^G(_U<>DU\AMO=LQ_RQOYPM]4&V MLUN[:+5.,.+HZ;,TN3BAR6.>AI\K3@025"Q5E73S&,^(21.[5+8GG'FN-BJ[ MM(2+=W0L%:AJ:$8-=)S2H!%%$?PCCT7_J'_Q1Z2VC MTCUA!O.KP]3@).T]E[C[3W#EX*9C5[@WCLO'[]W7G-LX^GIL@D..6H8U-8(* MN8@J%"FE_%NMKRMS);[WN,ES>&,'5X;K&H\E1RBACBK4P*J.JJ5,D91:#K<3 ']P+TMZ__V3\_ ` end